Please Wait
Applying Filters...
menu
    • menu
    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-24

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-17

    Virtual Booth

    Contact Supplier

    Menu

    Dalcetrapib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 177,429Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    DalCor Announces Launch of Dalcetrapib Clinical Trial for COVID-19
    DalCor Announces Launch of Dalcetrapib Clinical Trial for COVID-19

    11 Jan 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/01/11/2156093/0/en/DalCor-Announces-Launch-of-Dalcetrapib-Clinical-Trial-for-COVID-19.html

    GLOBENEWSWIRE
    11 Jan 2021
    Share Share
    Dalcor taps new CEO Fouzia Laghrissi-Thode as pivotal PhIII looms
    Dalcor taps new CEO Fouzia Laghrissi-Thode as pivotal PhIII looms

    14 Apr 2018

    // Amber Tong ENDPTS

    https://endpts.com/dalcor-taps-new-ceo-fouzia-laghrissi-thode-as-pivotal-phiii-looms-kelly-martin-settles-in-at-novan-edward-stewart-takes-over-commense/

    Amber Tong ENDPTS
    14 Apr 2018
    Share Share
    DalCor Randomizes First Patient in the DalGenE Phase 3 Cardiovascular Outcomes Tria
    DalCor Randomizes First Patient in the DalGenE Phase 3 Cardiovascular Outcomes Tria

    27 Apr 2016

    // PR NEWS WIRE

    http://www.prnewswire.com/news-releases/dalcor-randomizes-first-patient-in-the-dalgene-phase-3-cardiovascular-outcomes-trial-300256440.html

    PR NEWS WIRE
    27 Apr 2016
    Share Share
    New cardiovascular drugs raise concerns about pricing, efficacy
    New cardiovascular drugs raise concerns about pricing, efficacy

    21 Dec 2015

    // MMM

    http://www.mmm-online.com/therapeutic-focus/new-cardiovascular-drugs-raise-concerns-about-pricing-efficacy/article/460650/

    MMM
    21 Dec 2015
    Share Share
    Merck seeks oasis in CETP inhibitor desert
    Merck seeks oasis in CETP inhibitor desert

    18 Nov 2015

    // Phil Taylor PHARMATIMES

    http://www.pmlive.com/pharma_news/merck_seeks_oasis_in_cetp_inhibitor_desert_868680

    Phil Taylor PHARMATIMES
    18 Nov 2015
    Share Share
    Canadians hope $250 mln trial can revive failed Roche heart drug
    Canadians hope $250 mln trial can revive failed Roche heart drug

    11 Jun 2015

    // DAILY MAIL

    http://www.dailymail.co.uk/wires/reuters/article-3116808/Canadians-hope-250-mln-trial-revive-failed-Roche-heart-drug.html

    DAILY MAIL
    11 Jun 2015
    Share Share